Global Health (MEDANTA.BO) Earnings Analysis
Global Health (MEDANTA.BO) next reports earnings on 2026-07-30, consensus EPS 5.41 INR. Last quarter (2026-05-14) it beat with EPS 5.4 INR vs 4.53 INR est (+19.2%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 66.34.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MEDANTA.BO next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 5.41 INR |
| Revenue estimate | 12.03B |
MEDANTA.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 5.4 INR | 4.53 INR | +19.2% | Beat |
| 2026-02-04 | 4.75 INR | 5.31 INR | -10.5% | Miss |
| 2025-09-30 | 5.89 INR | 5.8 INR | +1.6% | Beat |
| 2025-08-08 | 5.91 INR | 5.24 INR | +12.8% | Beat |
| 2025-05-15 | 5.63 INR | 5.13 INR | +9.7% | Beat |
| 2024-11-14 | 4.87 INR | 4.4 INR | +10.7% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
MEDANTA.BO valuation and analyst view
| Trailing P/E | 66.34 |
|---|---|
| Trailing EPS | 20.714 INR |
| Price / book | 9.32 |
| Dividend yield | 0.04% |
| Market cap | 366.75B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Global Health (MEDANTA.BO)'s next earnings date?
Global Health is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 5.41 INR and revenue estimate of 12.03B.
Did MEDANTA.BO beat earnings last quarter?
In its 2026-05-14 report, MEDANTA.BO posted EPS of 5.4 INR versus a 4.53 INR estimate — a beat of 19.2%.
What is MEDANTA.BO's earnings track record?
Over the last 6 reported quarters with consensus data, MEDANTA.BO beat estimates 5 times (83%).
What is MEDANTA.BO's current P/E ratio and EPS?
MEDANTA.BO trades at a trailing P/E of 66.34 on trailing EPS of 20.714429297855073 INR.
What do analysts rate MEDANTA.BO?
MEDANTA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.